Recommendation of the President – Ilaris (canakinumab)
On 23 June 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendationNo. 78/2024 on the evaluation of the drug Ilaris (canakinumab) within the framework of the drug program “Treatment of patients with active form of rheumatoid arthritis and juvenile idiopathic arthritis (ICD-10: M05, M06, M08)”